BCRX Biocryst Pharmaceuticals Inc

Price (delayed)

$10.76

Market cap

$2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.07

Enterprise value

$2.21B

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of ...

Highlights
Biocryst Pharmaceuticals's quick ratio has surged by 129% YoY and by 14% QoQ
Biocryst Pharmaceuticals's gross margin has increased by 29% YoY and by 3.9% QoQ
BCRX's EPS is up by 11% YoY but it is down by 3.9% from the previous quarter
The net income has increased by 7% year-on-year but it has declined by 5% since the previous quarter
BCRX's equity has dropped by 119% year-on-year and by 53% since the previous quarter
BCRX's debt has soared by 112% YoY and by 3.3% QoQ

Key stats

What are the main financial stats of BCRX
Market
Shares outstanding
185.58M
Market cap
$2B
Enterprise value
$2.21B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
10.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.76
Earnings
Revenue
$188.03M
EBIT
-$121.18M
EBITDA
-$120.26M
Free cash flow
-$161.64M
Per share
EPS
-$1.07
Free cash flow per share
-$0.87
Book value per share
-$0.89
Revenue per share
$1.02
TBVPS
$2.85
Balance sheet
Total assets
$527.72M
Total liabilities
$691.94M
Debt
$613M
Equity
-$164.22M
Working capital
$430.7M
Liquidity
Debt to equity
-3.73
Current ratio
6.32
Quick ratio
5.96
Net debt/EBITDA
-1.78
Margins
EBITDA margin
-64%
Gross margin
99.1%
Net margin
-103.2%
Operating margin
-93.8%
Efficiency
Return on assets
-46.8%
Return on equity
N/A
Return on invested capital
-28.3%
Return on capital employed
-27.1%
Return on sales
-64.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
5.8%
1 week
11.85%
1 month
25.55%
1 year
-36.71%
YTD
-22.31%
QTD
-33.83%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$188.03M
Gross profit
$186.42M
Operating income
-$176.3M
Net income
-$193.97M
Gross margin
99.1%
Net margin
-103.2%
The operating margin has soared by 84% YoY and by 17% from the previous quarter
BCRX's net margin has soared by 84% YoY and by 12% QoQ
Biocryst Pharmaceuticals's gross margin has increased by 29% YoY and by 3.9% QoQ
Biocryst Pharmaceuticals's gross profit has increased by 24% from the previous quarter

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
10.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.76
BCRX's EPS is up by 11% YoY but it is down by 3.9% from the previous quarter
BCRX's equity has dropped by 119% year-on-year and by 53% since the previous quarter
The P/S is 60% lower than the 5-year quarterly average of 26.4 and 53% lower than the last 4 quarters average of 22.5
BCRX's revenue is up by 20% QoQ

Efficiency

How efficient is Biocryst Pharmaceuticals business performance
BCRX's ROS has soared by 88% YoY and by 17% from the previous quarter
The ROIC has soared by 78% YoY and by 25% QoQ
The company's return on assets rose by 44% YoY and by 10% QoQ

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 24% lower than its total liabilities
Biocryst Pharmaceuticals's current ratio has soared by 133% YoY and by 16% from the previous quarter
Biocryst Pharmaceuticals's quick ratio has surged by 129% YoY and by 14% QoQ
BCRX's equity has dropped by 119% year-on-year and by 53% since the previous quarter
BCRX's debt has soared by 112% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.